Trial Profile
A retrospective, observational study of Ipilimumab in patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 17 May 2016 New trial record